PRACTICE AND PROCEUDRE – application to set aside notice to produce served on prospective applicant – where prospective respondent’s nanopore sequencing devices may fall within the scope of one or more claims of patents owned by the prospective applicant – where category 1 seeks documents recording or evidencing prospective applicant’s belief that it may have the right to obtain relief from the prospective respondent – material sought is not reasonably likely to add to the relevant evidence in proceeding – where category 3 seeks documents recording or evidencing any delegation of authority relevant to the making of any decision by the prospective applicant to commence proceedings against the prospective respondent for patent infringement – where prospective applicant’s decision to commence proceedings is a decision of the board and its evidence does not refer to any such delegation – notice to produce be set aside
Related cases
-
Oxford Nanopore Technologies Plc v MGI Aust PL [2025] FCA 572
PRACTICE AND PROCEUDRE – application to set aside notice to produce served on prospective applicant – where prospective respondent’s nanopore sequencing devices may fall within the scope of one or more claims of patents owned by the prospective applicant – where category 1 seeks documents recording or evidencing prospective applicant’s belief that it may have…
-
MSA 4X4 Accessories PL v Clearview Towing Mirrors PL (Discovery) [2025] FCA 375
PATENTS – discovery – significant claim for damages following liability judgment – discovery application successful with modifications made to categories of discovery sought Related cases about Patent disputes Original article available at: https://www.judgments.fedcourt.gov.au/judgments/Judgments/fca/single/2025/2025fca0375For more information, see the original judgement.
-
Novartis AG v Pharmacor PL [2025] FCAFC 33
PATENTS – infringement – standard patent for a pharmaceutical composition containing certain active pharmaceutical ingredients – claim construction – whether primary judge erred in construction of claim as not including a pharmaceutical composition where the active pharmaceutical ingredient is in the form of a complex in which the ions are associated by non-covalent bonds –…
Original article available at: https://www.judgments.fedcourt.gov.au/judgments/Judgments/fca/single/2025/2025fca0572
For more information, see the original judgement.
